Patents Assigned to GRÜNENTHAL GMBH
  • Patent number: 9629807
    Abstract: The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: April 25, 2017
    Assignee: GRÜNENTHAL GMBH
    Inventors: Elisabeth Arkenau-Maric, Johannes Bartholomaeus, Heinrich Kugelmann
  • Publication number: 20170101397
    Abstract: The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    Type: Application
    Filed: October 7, 2016
    Publication date: April 13, 2017
    Applicant: GRÜNENTHAL GMBH
    Inventors: Stefan Schunk, Melanie Reich, René Michael Koenigs
  • Publication number: 20170101398
    Abstract: The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    Type: Application
    Filed: October 7, 2016
    Publication date: April 13, 2017
    Applicant: GRÜNENTHAL GMBH
    Inventors: Stefan SCHUNK, Melanie Reich, René Michael Koenigs
  • Publication number: 20170071862
    Abstract: The invention relates to a pharmaceutical dosage form which is particularly useful for the prevention of an overdose of the pharmacologically active ingredient contained therein after accidental or intentional simultaneous administration of a plurality of the dosage forms containing an overall supratherapeutic dose of the pharmacologically active ingredient.
    Type: Application
    Filed: September 9, 2016
    Publication date: March 16, 2017
    Applicant: GRÜNENTHAL GMBH
    Inventors: KLAUS WENING, Sebastian Schwier, Ulrike Bertram
  • Publication number: 20170049706
    Abstract: The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N.
    Type: Application
    Filed: September 2, 2016
    Publication date: February 23, 2017
    Applicant: Grünenthal GmbH
    Inventors: Elisabeth Arkenau-Maric, Johannes Bartholomäus
  • Patent number: 9562036
    Abstract: The invention relates to pyrrole carboxamides bearing a fluoromethyl-moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: February 7, 2017
    Assignee: GRÜNENTHAL GMBH
    Inventors: Melanie Reich, Stefan Schunk, Florian Jakob, Henning Steinhagen, Nils Damann, Michael Haurand, Marc Rogers, Kathy MacKenzie
  • Publication number: 20170000739
    Abstract: The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.
    Type: Application
    Filed: September 14, 2016
    Publication date: January 5, 2017
    Applicant: GRÜNENTHAL GMBH
    Inventors: Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
  • Publication number: 20160374965
    Abstract: The invention is directed to an immediate release capsule which mitigates the abuse of Tapentadol or physiologically acceptable salt thereof by direct intravenous injection. The capsule comprises a tamper resistant formulation which when mixed with water and heated, results in a turbid, bubbling mixture that is not injectable with a standard insulin syringe.
    Type: Application
    Filed: September 7, 2016
    Publication date: December 29, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: Ingo FRIEDRICH, Richard FUHRHERR, Silke MÖSCHTER, Simone WENGNER
  • Publication number: 20160374963
    Abstract: The invention relates to a dosage that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.
    Type: Application
    Filed: September 6, 2016
    Publication date: December 29, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: ELISABETH ARKENAU-MARIC, JOHANNES BARTHOLOMÄUS, HEINRICH KUGELMANN
  • Patent number: 9527832
    Abstract: The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: December 27, 2016
    Assignee: GRÜNENTHAL GMBH
    Inventors: Ingo Konetzki, Florian Jakob, Tobias Craan, Christian Hesslinger, Paul Ratcliffe, Antonio Nardi
  • Publication number: 20160367549
    Abstract: The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with potential for abuse (A), at least one synthetic or natural polymer (C), optionally delayed-release matrix auxiliary substances, physiologically acceptable auxiliary substances (B), optionally a wax (D) and optionally at least one delayed-release coating, component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.
    Type: Application
    Filed: September 2, 2016
    Publication date: December 22, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: JOHANNES BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
  • Publication number: 20160367484
    Abstract: The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of ?500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force.
    Type: Application
    Filed: August 31, 2016
    Publication date: December 22, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: Elisabeth ARKENAU-MARIC, Johanness BARTHOLOMÄUS, Heinrich KUGELMANN
  • Publication number: 20160367486
    Abstract: The present invention relates to a process for the production of an abuse-proofed dosage form containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer (C) with a breaking strength of at least 500 N, wherein the formulation mixture is combined with a solvent for the polymer (C) at least in quantities such that the formulation mixture is at least uniformly moistened, the at least moistened composition is optionally divided into sub-portions, dried and shaped to yield the dosage form.
    Type: Application
    Filed: September 2, 2016
    Publication date: December 22, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: ELISABETH ARKENAU-MARIC, JOHANNES BARTHOLOMÄUS
  • Publication number: 20160367487
    Abstract: The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N.
    Type: Application
    Filed: September 6, 2016
    Publication date: December 22, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: ELISABETH ARKENAU-MARIC, JOHANNES BARTHOLOMÄUS
  • Publication number: 20160367485
    Abstract: The present invention relates to a process for the production of an abuse-proofed dosage form containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer (C) with a breaking strength of at least 500 N, wherein the formulation mixture is combined with a solvent for the polymer (C) at least in quantities such that the formulation mixture is at least uniformly moistened, the at least moistened composition is optionally divided into sub-portions, dried and shaped to yield the dosage form.
    Type: Application
    Filed: September 2, 2016
    Publication date: December 22, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: Elisabeth ARKENAU-MARIC, Johannes BARTHOLOMÄUS
  • Publication number: 20160367501
    Abstract: The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of ?500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force.
    Type: Application
    Filed: August 29, 2016
    Publication date: December 22, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: Elisabeth ARKENAU-MARIC, Johannes BARTHOLOMÄUS, Heinrich KUGELMANN
  • Publication number: 20160361306
    Abstract: A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.
    Type: Application
    Filed: August 24, 2016
    Publication date: December 15, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: JOHANNES BARTHOLOMAEUS, HEINRICH KUGELMANN
  • Patent number: 9505724
    Abstract: The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: November 29, 2016
    Assignee: GRÜNENTHAL GMBH
    Inventors: Ingo Konetzki, Florian Jakob, Tobias Craan, Christian Hesslinger
  • Publication number: 20160338976
    Abstract: Summary: The invention relates to a monolithic pharmaceutical dosage form comprising a hot melt-extruded first segment (S1) and a second segment (S2); wherein the first segment (S1) contains at least a first pharmacologically active ingredient (A1) and/or the second segment (S2) contains at least a second pharmacologically active ingredient (A2); and the segment (S1) and/or the segment (S2) is tamper-resistant and/or exhibits a breaking strength of at least 300 N.
    Type: Application
    Filed: August 5, 2016
    Publication date: November 24, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: ANJA GEIßLER, KLAUS WENING, LUTZ BARNSCHEID, JANA PÄTZ
  • Publication number: 20160310486
    Abstract: A tamper-resistant pharmaceutical dosage form comprising two pharmacologically active ingredients, wherein the dosage form provides under in vitro conditions fast release, preferably immediate release according to Ph. Eur., of both pharmacologically active ingredients. The dosage form is useful for pharmaceutical combination therapy that is achieved by administering dosage forms containing more than one pharmacologically active ingredient as fixed-dose combinations.
    Type: Application
    Filed: April 22, 2016
    Publication date: October 27, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: Klaus WENING, Lutz BARNSCHEID, Anja GEIßLER, Jana DENKER, Jessica REDMER